Compare Equinix Inc (EQIX) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs Cassava Sciences Inc — how do they compare? Equinix Inc trades at $1,005.88 (market cap $100.85B), while Cassava Sciences Inc trades at $1.08 (market cap $53.14M). The key difference: Equinix Inc is far larger — about 1897.8× Cassava Sciences Inc's market cap, and Equinix Inc pays a 1.93% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| EQIX | FLNA | |
|---|---|---|
Market Cap | $100.85B | $53.14M |
Sector | Real Estate | Health |
52-Week High | $1.12K | $4.64 |
52-Week Low | $726.09 | $1.09 |
Enterprise Value | $121.14B | -$33.43M |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,005.31, down 1.78% today, with a bearish technical signal despite strong analyst support. The company reported mixed Q1 2026 earnings with a slight miss on EPS expectations but maintains robust revenue growth and profitability. Recent partnerships with Cisco and NVIDIA position EQIX well for AI infrastructure demand, though high valuation ratios and negative cash flow trends present challenges.
The outlook remains cautiously optimistic with 74.5% analyst buy ratings and a $1,110 consensus price target suggesting 10% upside. Key risks include elevated debt levels, aggressive capital expenditure, and competitive pressures in the data center REIT sector. The stock offers exposure to digital infrastructure growth but requires monitoring of cash flow sustainability.
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
